Loading...
Docoh

AbCellera Biologics (ABCL)

News

From Benzinga Pro
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
11 Aug 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.
Coinbase, Trade Desk, H&R Block And Some Other Big Gainers From Wednesday
11 Aug 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
U.S. stocks closed higher on Wednesday following the release of inflation data. Here is the list of some big stocks moving higher in the previous session.
Why Plug Power Is Trading Higher By Around 14%, Here Are 73 Stocks Moving In Wednesday's Mid-Day Session
10 Aug 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers BioAtla, Inc. (NASDAQ: BCAB) gained 50.1% to $5.42 following Q2 results. Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 39.5% to $2.0380.
Credit Suisse Maintains Outperform on AbCellera Biologics, Lowers Price Target to $34
10 Aug 22
News, Price Target, Analyst Ratings
Credit Suisse analyst Tiago Fauth maintains AbCellera Biologics (NASDAQ:ABCL) with a Outperform and lowers the price target from $40 to $34.
Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket
10 Aug 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt retirement and $11 million debt refinancing.
AbCellera Biologics Q2 EPS $(0.02), Inline, Sales $45.92M Miss $53.59M Estimate
9 Aug 22
Earnings, News
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 100 percent decrease over losses of $(0.01) per share from the same period last year.
Earnings Scheduled For August 9, 2022
9 Aug 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Versant Ventures Collaborates With AbCellera To Accelerate Drug Development For Its Portfolio Of Biotech Companies
27 Jul 22
News
AbCellera (NASDAQ:ABCL) and Versant Ventures today announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs. Versant
Piper Sandler Maintains Overweight on AbCellera Biologics, Raises Price Target to $22
26 Jul 22
News, Price Target, Analyst Ratings
Piper Sandler analyst Do Kim maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $21 to $22.

Press releases

From Benzinga Pro
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
21 Sep 22
Press Releases
AbCellera (NASDAQ:ABCL) today announced it has launched the second phase of its global headquarters expansion by breaking ground on its new facility in Vancouver, Canada. The 380,000-square-foot tech campus will include
AbCellera Reports Q2 2022 Business Results
9 Aug 22
Press Releases
Total revenue of $46 million, compared to $28 million in Q2 2021 Four program starts in the quarter bringing cumulative total to 88, up 47% from Q2 2021 Net loss of ($0.02) per share on a basic and diluted basis
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
3 Aug 22
Press Releases
Atlas' stealth-stage company will leverage AbCellera's technology to start and advance new drug programs with enhanced speed and capital efficiency AbCellera (NASDAQ:ABCL) and Atlas Venture announced a multi-target
Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies
27 Jul 22
Press Releases
AbCellera (NASDAQ:ABCL) and Versant Ventures today announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant's portfolio of biologics-focused biotechs. Versant and
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
12 Jul 22
Press Releases
AbCellera (NASDAQ:ABCL) will announce its second quarter 2022 financial results on Tuesday, August 9, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
29 Jun 22
Press Releases
Bebtelovimab continues to maintain neutralization activity against all known variants of interest and concern AbCellera (NASDAQ:ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified